| Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer PM Forde, J Spicer, S Lu, M Provencio, T Mitsudomi, MM Awad, E Felip, ... New England Journal of Medicine 386 (21), 1973-1985, 2022 | 1137 | 2022 |
| EMT subtype influences epithelial plasticity and mode of cell migration NM Aiello, R Maddipati, RJ Norgard, D Balli, J Li, S Yuan, T Yamazoe, ... Developmental cell 45 (6), 681-695. e4, 2018 | 586 | 2018 |
| Tumor cell-intrinsic factors underlie heterogeneity of immune cell infiltration and response to immunotherapy J Li, KT Byrne, F Yan, T Yamazoe, Z Chen, T Baslan, LP Richman, JH Lin, ... Immunity 49 (1), 178-193. e7, 2018 | 560 | 2018 |
| Detection of therapeutically targetable driver and resistance mutations in lung cancer patients by next-generation sequencing of cell-free circulating tumor DNA JC Thompson, SS Yee, AB Troxel, SL Savitch, R Fan, D Balli, ... Clinical Cancer Research 22 (23), 5772-5782, 2016 | 356 | 2016 |
| Key parameters of tumor epitope immunogenicity revealed through a consortium approach improve neoantigen prediction DK Wells, MM van Buuren, KK Dang, VM Hubbard-Lucey, KCF Sheehan, ... Cell 183 (3), 818-834. e13, 2020 | 335 | 2020 |
| Immune cytolytic activity stratifies molecular subsets of human pancreatic cancer D Balli, AJ Rech, BZ Stanger, RH Vonderheide Clinical Cancer Research 23 (12), 3129-3138, 2017 | 225 | 2017 |
| Foxm1 transcription factor is required for lung fibrosis and epithelial‐to‐mesenchymal transition D Balli, V Ustiyan, Y Zhang, IC Wang, AJ Masino, X Ren, JA Whitsett, ... The EMBO journal 32 (2), 231-244, 2013 | 178 | 2013 |
| First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743 S Peters, A Scherpereel, R Cornelissen, Y Oulkhouir, L Greillier, ... Annals of oncology 33 (5), 488-499, 2022 | 119 | 2022 |
| Foxm1 transcription factor is required for macrophage migration during lung inflammation and tumor formation D Balli, X Ren, FS Chou, E Cross, Y Zhang, VV Kalinichenko, TV Kalin Oncogene 31 (34), 3875-3888, 2012 | 91 | 2012 |
| Tumor immunity and survival as a function of alternative neopeptides in human cancer AJ Rech, D Balli, A Mantero, H Ishwaran, KL Nathanson, BZ Stanger, ... Cancer immunology research 6 (3), 276-287, 2018 | 83 | 2018 |
| Deletion of Forkhead Box M1 transcription factor from respiratory epithelial cells inhibits pulmonary tumorigenesis IC Wang, L Meliton, X Ren, Y Zhang, D Balli, J Snyder, JA Whitsett, ... PloS one 4 (8), e6609, 2009 | 79 | 2009 |
| Endothelial cell–specific deletion of transcription factor FoxM1 increases urethane-induced lung carcinogenesis D Balli, Y Zhang, J Snyder, VV Kalinichenko, TV Kalin Cancer research 71 (1), 40-50, 2011 | 75 | 2011 |
| Foxm1 expression in prostate epithelial cells is essential for prostate carcinogenesis Y Cai, D Balli, V Ustiyan, L Fulford, A Hiller, V Misetic, Y Zhang, ... Journal of Biological Chemistry 288 (31), 22527-22541, 2013 | 68 | 2013 |
| An integrated flow cytometry-based platform for isolation and molecular characterization of circulating tumor single cells and clusters N Bhagwat, K Dulmage, CH Pletcher Jr, L Wang, W DeMuth, M Sen, ... Scientific reports 8 (1), 5035, 2018 | 64 | 2018 |
| FOXM1 activates AGR2 and causes progression of lung adenomas into invasive mucinous adenocarcinomas D Milewski, D Balli, V Ustiyan, T Le, H Dienemann, A Warth, K Breuhahn, ... PLoS genetics 13 (12), e1007097, 2017 | 58 | 2017 |
| Loss of FOXM1 in macrophages promotes pulmonary fibrosis by activating p38 MAPK signaling pathway C Goda, D Balli, M Black, D Milewski, T Le, V Ustiyan, X Ren, ... PLoS Genetics 16 (4), e1008692, 2020 | 44 | 2020 |
| First-line nivolumab plus ipilimumab with chemotherapy versus chemotherapy alone for metastatic NSCLC in CheckMate 9LA: 3-year clinical update and outcomes in patients with … LG Paz-Ares, TE Ciuleanu, M Cobo, J Bennouna, M Schenker, Y Cheng, ... Journal of Thoracic Oncology 18 (2), 204-222, 2023 | 40 | 2023 |
| MYC Levels Regulate Metastatic Heterogeneity in Pancreatic Adenocarcinoma R Maddipati, RJ Norgard, T Baslan, KS Rathi, A Zhang, A Saeid, ... Cancer discovery 12 (2), 542-561, 2022 | 40 | 2022 |
| Calcium signaling induces a partial EMT RJ Norgard, JR Pitarresi, R Maddipati, NM Aiello‐Couzo, D Balli, J Li, ... EMBO reports 22 (9), e51872, 2021 | 35 | 2021 |
| Image analysis reveals molecularly distinct patterns of TILs in NSCLC associated with treatment outcome R Ding, P Prasanna, G Corredor, C Barrera, P Zens, C Lu, P Velu, P Leo, ... NPJ precision oncology 6 (1), 33, 2022 | 26 | 2022 |
